SCHEMBL25378347

SCHEMBL25378347

CS(=O)(=O)N(c1ncc(-c2nccnc2Oc2ccc(C(F)(F)F)cc2)cc1Cl)S(C)(=O)=O

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 7/20 0.41
▸ SMN1; SMN2 Q16637 6/20 0.41
▸ ALDH1A1 P00352 5/20 0.40
▸ MDM2 Q00987 1/20 0.40
▸ HTT P42858 4/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ MAPT P10636 3/20 0.39
▸ POLB P06746 1/20 0.39
▸ KMT2A Q03164 2/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ XBP1 P17861 1/20 0.38
▸ HPGD P15428 1/20 0.37
▸ LIPE Q05469 1/20 0.37
▸ SCN9A Q15858 2/20 0.36
▸ FFAR1 O14842 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30482519 1.00 LMNA (0.41) LMNASMN1; SMN2ALDH1A1MDM2HTT
SCHEMBL25380419 0.82 LMNA (0.43) LMNASMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL30519311 0.80 SLC6A2 (0.36) LMNASMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL25341461 0.80 SLC6A2 (0.36) LMNASMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL25377702 0.78 RAB9A (0.42) LMNASMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL25375690 0.78 SMN1; SMN2 (0.41) LMNASMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL30482509 0.78 KMT2A (0.41) LMNASMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL25379199 0.78 KMT2A (0.41) LMNASMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL25343113 0.77 PTGS2 (0.35) LMNASMN1; SMN2ALDH1A1
SCHEMBL30519319 0.77 PTGS2 (0.35) LMNASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023146512-A1 COMPOUNDS AND METHODS OF USE THEREOF VIVACE THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
WO-2023146512-A1 COMPOUNDS AND METHODS OF USE THEREOF VIVACE THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
Send feedback